CytoDyn Inc. CYDY Stock Price is up 33%, but there is more… Urgent Report
CytoDyn Inc. CYDY stock price is up 33% in the last 5month in PPS & volume is up 35%, but is it over for this breakout stock?
In this in depth report, I look at 5 KPIs: Technical Analysis, Volume, News Cycle, Fundamentals & awareness campaigns. I believe the stock market is not gambling, it is also not fool proof, but I have developed a dependable system. I have found some critical components to success for CYDY, tell me what you think.
Before we get started, I like being methodical and easy to understand so I have developed a ranking system for my stocks. I call it, Alexander Goldman’s “HOT Stock Ranking!”
The official heat level for CYDY is, a 🔥🔥🔥 3 out of 4
Before I get ahead of myself and just jump right into this exciting breakout stock, I wanted to introduce myself.
Hello 🙋♂️ My name is Alexander Goldman. I have been trading small cap stocks, breakout stocks and trending stocks for 20 years now. I’m accredited for establishing the coveted HOT Stock Reporting system for breakout stocks.
To find out more about my story, CLICK HERE
[thrive_leads id=’28419′]
CytoDyn Inc. Company Information
Company Name: CytoDyn Inc.
Ticker: CYDY
Exchange: OTC
Website: https://www.cytodyn.com/
CytoDyn Company Summary:
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, Cancer, graft-versus-host disease (GVHD), and COVID-19. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.
CYDY stock price is due to News?
April 12th
Announced the publication of a peer-reviewed research paper entitled “Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species” in the open-access journal PLOS Pathogens.
Trending Stock CYDY 5 Day Chart
CYDY Stock Price HOT Stock Grade:
The official heat level for CYDY is, a 🔥🔥🔥 3 out of 4 . Here are my takeaways on it and why it is just a 3 out of 4. Do you agree?
CYDY Trading Volume
The volume, is trading at an increase of 33% over the average which indicates a higher demand in the stock.
Trading 101: volume is measured in the number of shares traded. Traders look to volume to determine liquidity and combine changes in volume with technical indicators to make trading decisions. So, let’s take a look at the technical indicators.
CYDY Technicals
The technical analysis “chart reading”, it is bearish on the 5 day and in the 1 day chart. I do not like it at this time.
Trading 101: Technical indicators are technical tools that help in analyzing the movement in the stock prices whether the ongoing trend is going to continue or reverse. It helps the traders to make entry and exit decisions of a particular stock. Technical indicators can be leading or lagging indicators.
CYDY News Cycle
The news, there is incredible news “Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species”
CYDY Fundamentals
The fundamentals, there is exciting financial filings associated with this stock, they have almost doubled since 2019 revenue numbers.
Trading 101: Fundamental trading is a method where a trader focuses on company-specific events to determine which stock to buy and when to buy it. Trading on fundamentals is more closely associated with a buy-and-hold strategy rather than short-term trading.
CYDY Awareness
Marketing efforts “Awareness Campaigns”, I have not found marketing efforts around the investor awareness of this company. Hence the 3 out of 4. Do you agree? Write me a line at [email protected]
Again, two heads are better than one, let’s work together to have the best trading year of our lives!
To receive my 🔥🔥🔥🔥 HOT stock as a thank you for joining our FREE newsletter, sign up today.
To find out more about my story, CLICK HERE
👇 Sign up for our newsletter to get the latest 🔥🔥🔥🔥 HOT stocks and we can compare notes!👇
[thrive_leads id=’28419′]
CytoDyn Inc. CYDY Stock Price is so consistent, can it go higher? Urgent Report
CytoDyn Inc. CYDY stock price is up -10% in the last 5 days & volume is up 17%, but is it over for this breakout stock?
There is an old adage, “two heads are better than one”, so let’s collaborate on CYDY and compare notes.
In this in depth report, I look at 5 KPIs: Technical Analysis, Volume, News Cycle, Fundamentals & awareness campaigns. I believe the stock market is not gambling, it is also not fool proof, but I have developed a dependable system. I have found some critical components to success for CYDY, tell me what you think.
Before we get started, I like being methodical and easy to understand so I have developed a ranking system for my stocks. I call it, Alexander Goldman’s “HOT Stock Ranking!”
The official heat level for CYDY is, a 🔥🔥🔥 3 out of 4
Before I get ahead of myself and just jump right into this exciting breakout stock, I wanted to introduce myself.
Hello 🙋♂️ My name is Alexander Goldman. I have been trading small cap stocks, breakout stocks and trending stocks for 20 years now. I’m accredited for establishing the coveted HOT Stock Reporting system for breakout stocks.
To find out more about my story, CLICK HERE
[thrive_leads id=’28419′]
CytoDyn Inc. Company Information
Company Name: CytoDyn Inc.
Ticker: CYDY
Exchange: OTC
Website: https://www.cytodyn.com/
CytoDyn Company Summary:
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, Cancer, graft-versus-host disease (GVHD), and COVID-19. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.
CYDY stock price is due to News?
April 12th
Announced the publication of a peer-reviewed research paper entitled “Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species” in the open-access journal PLOS Pathogens.
Trending Stock CYDY 5 Day Chart
CYDY Stock Price HOT Stock Grade:
The official heat level for CYDY is, a 🔥🔥🔥 3 out of 4 . Here are my takeaways on it and why it is just a 3 out of 4. Do you agree?
CYDY Trading Volume
The volume, is trading at an increase of 18% over the average which indicates a higher demand in the stock.
Trading 101: volume is measured in the number of shares traded. Traders look to volume to determine liquidity and combine changes in volume with technical indicators to make trading decisions. So, let’s take a look at the technical indicators.
CYDY Technicals
The technical analysis “chart reading”, it is bearish on the 5 day but consolidating in the 1 day chart.
Trading 101: Technical indicators are technical tools that help in analyzing the movement in the stock prices whether the ongoing trend is going to continue or reverse. It helps the traders to make entry and exit decisions of a particular stock. Technical indicators can be leading or lagging indicators.
CYDY News Cycle
The news, there is incredible news “Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species”
CYDY Fundamentals
The fundamentals, there is exciting financial filings associated with this stock, they have almost doubled since 2019 revenue numbers.
Trading 101: Fundamental trading is a method where a trader focuses on company-specific events to determine which stock to buy and when to buy it. Trading on fundamentals is more closely associated with a buy-and-hold strategy rather than short-term trading.
CYDY Awareness
Marketing efforts “Awareness Campaigns”, I have not found marketing efforts around the investor awareness of this company. Hence the 3 out of 4. Do you agree? Write me a line at [email protected]
Again, two heads are better than one, let’s work together to have the best trading year of our lives!
To receive my 🔥🔥🔥🔥 HOT stock as a thank you for joining our FREE newsletter, sign up today.
To find out more about my story, CLICK HERE
👇 Sign up for our newsletter to get the latest 🔥🔥🔥🔥 HOT stocks and we can compare notes!👇
[thrive_leads id=’28419′]
CytoDyn (CYDY) Stock Extends Fall: Fall Another 10%
For the past couple of years, biotech firm CytoDyn (OTCMKTS:CYDY) has come into prominence due to its work with leronlimab, which is known to work against a range of conditions.
On Wednesday, the CytoDyn stock was in action but it actually recoded a decline of as much as 10%. There was no new about the company yesterday that could have led to the decline. However, in this sort of a situation, it could be a good idea to take a look at some recent development. Back on May 6, the company announced that it was on the verge of starting the trial of leronlimab in patients who were suffering from severe symptoms of COVID 19.
The trial is going to be conducted in collaboration with the academic research organisation Albert Einstein Israelite Hospital (AEIH). The trials are going to be conducted at as many as 45 clinical sites all across the United States. In this regard, it is necessary to note that the Phase III trials are expected to deliver the data that is going to be required by ANVISA, the regulatory body in Brazil, for approving leronlimab for the treatment of COVID 19 infected patients in the country.
It was also announced that CytoDyn is looking to have an interim analysis of the data through October and November. The trial is going to enroll 120 patients suffering from critical symptoms of COVID 19. Last month, the company had announced that it signed an exclusive supply and distribution agreement with Chiral Pharma Corporation. By way of this agreement, CytoDyn is going to supply Chiral with as many as 200000 vials of leronlimab that are going to be administered to critically ill COVID 19 patients in Philippines. These are all important developments and despite the fall in the CytoDyn stock yesterday, investors could consider tracking the stock.